Studies have shown that more than one in five people who travel on planes suffer from a cold or the flu after the flight. BioSure Global, the team behind the first CE marked HIV self-test, is launching BioSURE PRO Protective Nasal Spray – proven, safe and effective for 6-hours per use – creating an invisible physical barrier that helps prevent infections caused by rotavirus A (sickness and diarrhoea) RSV (common colds), influenzas (flu) and coronaviruses including COVID-19 before they even start – and before you make your journey.
Microbiologists have tested planes and found that germs are commonplace, and can survive for hours or days after the passenger who brought them on board has departed. Some of the 200 or so viruses that can cause the common cold can infect people for up to 18 hours after they have left the body, and flu viruses can infect people for up to eight hours after being let loose.
This innovative, patented Nasal Spray has a unique action which creates a barrier in the nasopharynx that blocks the attachment of airborne viruses. BioSURE PRO Protective Nasal Spray coats the nasal membranes and forms a film to create an invisible, physical barrier that stops colds, flus and coronaviruses from attaching to the cells in your nose. If the viruses can’t connect, they can’t infect.
Suitable for daily use, for all aged 12 and over, BioSURE PRO costs just £14.95 and is proven to be effective for 6 hours per application and can be reapplied every 6 hours for continuous protection. With 400 sprays per bottle, it means there is 3 months supply if used daily, which equates to only 2.5p/hour of protection. BioSURE PRO is not a medicine and uses natural and food safe ingredients means it is safe for prolonged daily use, with no side effects or risk of long term dependencies. Available online at www.bebiosure.com , on Amazon and from the 760 strong Well Pharmacy group, the product is available now across the UK online and in local chemists.
BioSure Global headquartered in the UK are developing, manufacturing and distributing world-class medical devices. Headed up by award-winning Global CEO Brigette Bard, the team have decades of experience working with medical devices in global markets and believe this latest product launch is highly relevant for businesses to help keep their workforce well and reduce absenteeism and increase peace of mind.
BioSURE Global CEO Brigette Bard confirms it’s the perfect product for those planning on travelling: “There’s nothing more disconcerting than sitting close to someone on a plane who can’t stop coughing or sneezing. You can almost see the microbes coming your way! We have always been passionate about giving people products so they can feel in control and we’ve developed BioSURE PRO to stop the viruses before they even start. It’s effective at blocking the 3 ‘tripledemic’ viruses RSV, flu and COVID-19 but we’re looking at a behavioural change for people to take action before they catch an infection, rather than reacting when they have symptoms”
Dr Abdul Gaffar, lead of the award winning team of scientists that developed the formula stated, “BioSURE PRO’s unique formula contains ELAH (Ethyl Lauroyl Arginate HCL), which prevents the virus from attaching to the nasal passages — essentially stopping the virus before it can reach a dangerous level. When it gets into nasal passages, it starts replicating very fast, and, when it replicates and reaches certain levels, it is able to move to other areas of the body, especially the lungs, where it creates havoc. We interrupt that process.”
Clinical studies have demonstrated BioSURE PRO’s ability to stop viruses before they gain entry to the body, by blocking viral attachment to the nasopharynx. Independently tested against most common flus, colds and COVID-19 delta and omicron variants BioSURE PRO prevented viral replication in cells treated with the spray vs a control group of untreated cells. Four times more subjects remained infection-free after a 6-day study period with testing against Delta variant specifically.
BioSURE PRO Protective Nasal Spray is now UKCA marked and MHRA registered. It is undergoing Notified Body CE marking for sales into Europe, with certification anticipated Q1 2023. The award winning formula is already proving successful in the USA under the Covixyl brand name.
Original article can be found at: